GlassScriptPhysician profile
Abraham Krepostman
NPI 1285661546
$6,200.10
in general payments reported to CMS, 2019-2025
31 companies · $684 in 2025
The $684 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,073 · 2020: $418 · 2021: $904 · 2022: $1,070 · 2023: $1,180 · 2024: $872 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,641 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,640.97 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,176.67 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $737.77 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $595.92 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $486.66 | 2021-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $417.10 | 2020-2025 | |
| Amgen INC. | $386.89 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $284.37 | 2019-2024 | Farxiga |
| Boston Scientific Corporation | $244.07 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $222.48 | 2019-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $207.79 | 2023-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $184.08 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $179.29 | 2019-2023 | |
| Actelion Pharmaceuticals US, INC. | $148.93 | 2019-2024 | Opsumit, Uptravi |
| Novo Nordisk INC | $103.43 | 2019-2021 | |
| Lundbeck LLC | $98.77 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $96.44 | 2022-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Medtronic, INC. | $87.61 | 2022-2023 | Corevalve Evolut R, Micra |
| Kestra Medical Technology Services, INC. | $76.77 | 2024-2025 | Assure Wcd |
| Kowa Pharmaceuticals America, INC. | $70.96 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $55.76 | 2019-2021 | |
| Medtronic USA, INC. | $49.38 | 2019 | |
| Esperion Therapeutics, INC. | $48.36 | 2020-2021 | |
| Medtronic Vascular, INC. | $40.37 | 2019 | |
| Scpharmaceuticals INC. | $40.01 | 2024 | |
| Baxter Healthcare | $31.10 | 2024-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Philips North America LLC | $30.66 | 2025 | Extended Holter, Holter |
| Daiichi Sankyo INC. | $30.16 | 2019-2020 | |
| Abbott Laboratories | $24.22 | 2025 | Jot Dx |
| Osprey Medical INC | $16.00 | 2019 | |
| Bardy Diagnostics, INC. | $14.84 | 2022 | |
| Lilly USA, LLC | $13.24 | 2023 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abraham Krepostman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.